Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Holding(s) in Company

9 Oct 2025 07:00

RNS Number : 6418C
Tissue Regenix Group PLC
09 October 2025
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Tissue Regenix Group plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Lombard Odier Asset Management (Europe) Limited

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

Disclosure on behalf of accounts managed on a discretionary basis by Lombard Odier Investment Managers group.

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

07.10.2025

6. Date on which issuer notified (DD/MM/YYYY):

08.10.2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

10.95%

10.95%

7,819,294

Position of previous notification (if

applicable)

11.12%

11.12%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BNTXR104

7,819,294

10.95%

SUBTOTAL 8. A

7,819,294

10.95%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

x

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London

Date of completion

08.10.2025

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUWUKRVOURRAA
Date   Source Headline
28th Jun 20217:00 amRNSCompletion of phase 1 of new US facility expansion
23rd Jun 20216:08 pmRNSDirector/PDMR Shareholding
10th Jun 20214:17 pmRNSHolding(s) in Company
3rd Jun 20211:37 pmRNSResult of AGM
11th May 20217:00 amRNSDirector/PDMR Shareholding
10th May 202110:00 amRNSDirector/PDMR Shareholding
5th May 20217:00 amRNSGrant of share options
29th Apr 20214:11 pmRNSHolding(s) in Company
28th Apr 20217:00 amRNSFinal Results and Notice of AGM
20th Apr 20211:07 pmRNSHolding(s) in Company
20th Apr 202112:10 pmRNSHolding(s) in Company
19th Apr 20217:00 amRNSNotice of Results
13th Apr 20217:00 amRNSHolding(s) in Company
1st Apr 20214:40 pmRNSSecond Price Monitoring Extn
1st Apr 20214:36 pmRNSPrice Monitoring Extension
18th Mar 20217:00 amRNSInitial phase of US facility expansion complete
26th Feb 20217:00 amRNSDirectorate Change
19th Feb 20213:52 pmRNSHolding(s) in Company
11th Feb 20217:00 amRNSMove to Electronic Reporting
8th Feb 20217:00 amRNSTrading Update
5th Feb 20214:40 pmRNSSecond Price Monitoring Extn
5th Feb 20214:35 pmRNSPrice Monitoring Extension
21st Jan 20217:00 amRNSAppointment of Chief Financial Officer
6th Jan 20213:58 pmRNSPDMR Dealings
5th Jan 20217:00 amRNSConfirmation of Board appointments
4th Jan 202111:26 amRNSHoldings in Company
24th Dec 202012:56 pmRNSIssue of Equity & Total Voting Rights Replacement
24th Dec 202011:15 amRNSHoldings in Company
23rd Dec 20209:51 amRNSIssue of Equity and Total Voting Rights
4th Dec 20207:00 amRNSBoard Changes
3rd Dec 20204:54 pmRNSHoldings in Company
2nd Dec 20207:00 amRNSFirst delivery of OrthoPure® XT
27th Nov 20209:09 amRNSHoldings in Company
26th Nov 20204:02 pmRNSHoldings in Company
17th Nov 20207:00 amRNSAppointment of CEO
6th Nov 20207:00 amRNSHoldings in Company
29th Oct 20207:00 amRNSHoldings in Company
29th Oct 20207:00 amRNSChange of Registered Office
26th Oct 20204:50 pmRNSHoldings in Company
7th Oct 20201:50 pmEQSHardman & Co Research: Tissue Regenix (TRX): Funded through to profitability
28th Sep 202012:24 pmRNSHoldings in Company
16th Sep 20207:42 amRNSHoldings in Company
15th Sep 20204:40 pmRNSSecond Price Monitoring Extn
15th Sep 20204:35 pmRNSPrice Monitoring Extension
14th Sep 20205:33 pmRNSHoldings in Company
2nd Sep 20207:00 amRNSUnaudited Interim Results
27th Aug 20207:00 amRNSNotice of Interim Results & Investor Presentation
24th Aug 20207:00 amRNSUK distribution partner for OrthoPure® XT
18th Aug 202011:27 amRNSHoldings in Company
17th Aug 20207:00 amRNSRelocation of UK office and manufacturing facility

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.